Dogwood Therapeutics (DWTX) EBT (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly EBT of -$107753.0 for Q1 2026, up 99.0% year-over-year from -$54148.3 in Q1 2025, and up 99.67% quarter-over-quarter from -$32.5 million in Q4 2025.
Dogwood Therapeutics (DWTX) EBT (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported EBT for 7 consecutive years, with -$107753.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 99.0% year-over-year to -$107753.0; the TTM figure through Mar 2026 stood at -$36.8 million (down 68.79% YoY), while the FY2025 annual figure was -$34.0 million, down 175.59% from the prior year.
- EBT improved to -$107753.0 in Q1 2026 per DWTX's latest filing, from -$32.5 million in the prior quarter.
- Across five years, EBT topped out at -$107753.0 in Q1 2026 and bottomed at -$32.5 million in Q4 2025.
- Historically, EBT has averaged -$4.6 million across 5 years, with a median of -$2.0 million in 2022.
- Annual changes were most pronounced in 2025 — EBT sank 731.26% — and 2026, when it surged 99.0%.
- Dogwood Therapeutics' EBT stood at -$2.0 million in 2022, then jumped by 46.04% to -$1.1 million in 2023, then sank by 600.56% to -$7.7 million in 2024, then tumbled by 319.91% to -$32.5 million in 2025, then surged by 99.67% to -$107753.0 in 2026.
- Business Quant data shows DWTX's EBT at -$107753.0 in Q1 2026, -$32.5 million in Q4 2025, and -$417782.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 81.49 Mn |
| 10 | Dogwood Therapeutics | 80.89 Mn | 80.89 Mn | - | -14.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107,753.00 |
| Dec 31, 2025 | -32.45 Mn |
| Sep 30, 2025 | -417,782.00 |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | -10.73 Mn |
| Dec 31, 2024 | -7.73 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -1.44 Mn |
| Mar 31, 2023 | -1.52 Mn |
| Dec 31, 2022 | -2.04 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Jun 30, 2022 | -3.67 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -4.51 Mn |
| Sep 30, 2021 | -4.11 Mn |
| Jun 30, 2021 | -4.28 Mn |